Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma—experience at two centres

BACKGROUND: Ramucirumab is a VEGFR-2 antibody that has proven to prolong overall survival (OS) in patients with pretreated metastatic gastric/gastrooesophageal junction (GEJ) adenocarcinoma. We present data from patients treated with ramucirumab and paclitaxel or FOLFIRI after failure of at least on...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Gastrointest Oncol
Asıl Yazarlar: Vogl, Ursula M., Vormittag, Laurenz, Winkler, Thomas, Kafka, Alice, Weiser-Jasch, Olivia, Heinrich, Bettina, Roider-Schur, Sophie, Andalibi, Haleh, Autzinger, Eva, Schima, Wolfgang, Klaus, Alexander, Zacherl, Johannes, Wimberger, Günter Michael, Öhler, Leopold
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AME Publishing Company 2020
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212104/
https://ncbi.nlm.nih.gov/pubmed/32399277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2020.03.10
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller